JP2017537627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537627A5 JP2017537627A5 JP2017529682A JP2017529682A JP2017537627A5 JP 2017537627 A5 JP2017537627 A5 JP 2017537627A5 JP 2017529682 A JP2017529682 A JP 2017529682A JP 2017529682 A JP2017529682 A JP 2017529682A JP 2017537627 A5 JP2017537627 A5 JP 2017537627A5
- Authority
- JP
- Japan
- Prior art keywords
- signaling domain
- antigen receptor
- chimeric antigen
- domain
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000011664 signaling Effects 0.000 claims 50
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 125000006850 spacer group Chemical group 0.000 claims 22
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 20
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 20
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 3
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 1
- 102100033467 L-selectin Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022001433A JP7252379B2 (ja) | 2014-12-05 | 2022-01-07 | Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088423P | 2014-12-05 | 2014-12-05 | |
| US62/088,423 | 2014-12-05 | ||
| PCT/US2015/064303 WO2016090369A1 (en) | 2014-12-05 | 2015-12-07 | Cs1 targeted chimeric antigen receptor-modified t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022001433A Division JP7252379B2 (ja) | 2014-12-05 | 2022-01-07 | Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537627A JP2017537627A (ja) | 2017-12-21 |
| JP2017537627A5 true JP2017537627A5 (enExample) | 2019-01-17 |
| JP7098325B2 JP7098325B2 (ja) | 2022-07-11 |
Family
ID=55069093
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529682A Active JP7098325B2 (ja) | 2014-12-05 | 2015-12-07 | Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
| JP2022001433A Active JP7252379B2 (ja) | 2014-12-05 | 2022-01-07 | Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022001433A Active JP7252379B2 (ja) | 2014-12-05 | 2022-01-07 | Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10821161B2 (enExample) |
| EP (2) | EP3227315B1 (enExample) |
| JP (2) | JP7098325B2 (enExample) |
| KR (1) | KR102558502B1 (enExample) |
| CN (2) | CN114085856A (enExample) |
| AU (2) | AU2015357485B2 (enExample) |
| BR (1) | BR112017011893A2 (enExample) |
| CA (1) | CA2969704C (enExample) |
| IL (3) | IL290459B2 (enExample) |
| MX (2) | MX384964B (enExample) |
| RU (1) | RU2727451C2 (enExample) |
| WO (1) | WO2016090369A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP4219687B1 (en) | 2014-04-23 | 2024-08-14 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| WO2016090369A1 (en) | 2014-12-05 | 2016-06-09 | City Of Hope | Cs1 targeted chimeric antigen receptor-modified t cells |
| MX389057B (es) | 2015-01-26 | 2025-03-20 | Allogene Therapeutics Inc | Sistemas de receptor de antigeno quimerico impulsado por mab para clasificar/reducir celulas inmunes diseñadas. |
| JP6957471B2 (ja) | 2015-09-11 | 2021-11-02 | バイオセプター・（ユーケー）・リミテッド | キメラ抗原受容体およびその使用 |
| EP3408297A2 (en) | 2016-01-29 | 2018-12-05 | Med Manor Organics, (P) Ltd | A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof |
| KR102522622B1 (ko) | 2016-04-01 | 2023-04-18 | 카이트 파마 인코포레이티드 | Bcma 결합 분자 및 그의 사용 방법 |
| ES2930058T3 (es) | 2016-04-01 | 2022-12-05 | Kite Pharma Inc | Receptores quiméricos y métodos de uso de los mismos |
| SI3436079T1 (sl) | 2016-04-01 | 2022-01-31 | Kite Pharma, Inc. | Himerni antigen in T celični receptorji ter način uporabe |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| US11547748B2 (en) | 2016-06-30 | 2023-01-10 | Hoffmann-La Roche Inc. | Adoptive t-cell therapy |
| CN105949324B (zh) * | 2016-06-30 | 2019-08-27 | 上海恒润达生生物科技有限公司 | 靶向gpc3的嵌合抗原受体及其用途 |
| EP3518944A4 (en) * | 2016-09-30 | 2020-06-17 | Baylor College of Medicine | ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN |
| US12083148B2 (en) | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| WO2018169922A2 (en) | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| MX2019011225A (es) * | 2017-03-20 | 2020-01-21 | Células t modificadas por el receptor de antígeno quimérico dirigidas a cs1 para el tratamiento de la amiloidosis al. | |
| CR20190440A (es) | 2017-03-27 | 2019-11-12 | Hoffmann La Roche | Receptores de unión a antígeno mejorados |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| CA3061546C (en) | 2017-04-28 | 2023-09-19 | Julius-Maximilians-Universitat Wurzburg | Ror1-specific chimeric antigen receptors (car) with humanized targeting domains |
| CA3071303A1 (en) * | 2017-08-01 | 2019-02-07 | Julius-Maximilians-Universitat Wurzburg | Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia |
| KR20220035977A (ko) | 2017-08-11 | 2022-03-22 | 아이디에이씨 홀딩스, 인크. | 다수의 액세스 네트워크 간의 트래픽 조종 및 스위칭 |
| MA50855A (fr) * | 2017-11-01 | 2020-09-09 | Juno Therapeutics Inc | Procédé de génération de compositions thérapeutiques de cellules modifiées |
| US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| KR20250137191A (ko) * | 2017-11-14 | 2025-09-17 | 아르셀엑스, 인크. | D-도메인 함유 폴리펩타이드 및 이의 용도 |
| US11390655B2 (en) | 2017-11-16 | 2022-07-19 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| AU2019209432B2 (en) | 2018-01-22 | 2026-01-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| AU2019222550B2 (en) | 2018-02-16 | 2022-10-27 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
| TW202000229A (zh) | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| EP3797164A4 (en) * | 2018-05-21 | 2022-03-02 | Biosceptre (Aust) Pty Ltd | CHEMERA ANTIGEN RECEPTORS WITH MODIFIED BINDING DOMAINS AND USES THEREOF |
| WO2020009868A1 (en) * | 2018-07-03 | 2020-01-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-slamf7 chimeric antigen receptors |
| US12281152B2 (en) | 2018-08-01 | 2025-04-22 | City Of Hope | TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG72-positive tumors |
| CN112469734A (zh) * | 2018-08-03 | 2021-03-09 | 南京驯鹿医疗技术有限公司 | 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用 |
| CA3122762A1 (en) | 2018-12-12 | 2020-06-18 | Kite Pharma, Inc. | Chimeric antigen and t cell receptors and methods of use |
| IL316764A (en) | 2019-04-03 | 2025-01-01 | Prec Biosciences Inc | Genetically modified immune cells containing shRNA-targeted microRNA (shRNAmir) |
| CA3141812A1 (en) * | 2019-05-24 | 2020-12-03 | City Of Hope | Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies |
| EP3986923A1 (en) * | 2019-06-19 | 2022-04-27 | Julius-Maximilians-Universität Würzburg | Ultramodular igg3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design |
| CN112442126B (zh) * | 2019-09-04 | 2022-07-29 | 杭州济元基因科技有限公司 | 一种抗人cs1抗原的单克隆抗体及其car-t细胞 |
| JP2023525049A (ja) * | 2020-05-08 | 2023-06-14 | シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート | ナチュラルキラー細胞を標的とするキメラ抗原受容体（ｃａｒ） |
| US20230220419A1 (en) * | 2020-05-27 | 2023-07-13 | The Medical College Of Wisconsin, Inc. | Improved Lentiviral Vector Transfer Plasmid and Methods of Use |
| US20230295331A1 (en) * | 2020-08-06 | 2023-09-21 | Promab Biotechnologies, Inc. | Cs1- antibody and anti-cs1-car-t cells |
| US20230287129A1 (en) * | 2020-08-10 | 2023-09-14 | Julius-Maximilians-Universität Würzburg | Siglec-6-binding polypeptides |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2022206941A1 (zh) * | 2021-04-02 | 2022-10-06 | 克莱格医学有限公司 | Cs1工程化细胞及其组合物 |
| WO2023107898A1 (en) * | 2021-12-06 | 2023-06-15 | The Children's Hospital Of Philadelphia | Dual targeting of pediatric malignancies through car t-cells secreting bispecific innate immune cell engagers (bices) |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| CN119095881A (zh) * | 2022-03-25 | 2024-12-06 | 豪夫迈·罗氏有限公司 | 经改善的嵌合受体 |
| CN120344563A (zh) * | 2022-12-02 | 2025-07-18 | 广州荔泰生物科技有限公司 | 人cs1 car-t细胞 |
| CN119019554B (zh) * | 2023-05-25 | 2025-08-12 | 东莞市朋志生物科技有限公司 | 抗白介素6抗体、检测白介素6的试剂和试剂盒 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0486572B1 (en) | 1989-08-11 | 1998-01-07 | Amrad Corporation Limited | Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
| WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| NZ597168A (en) | 2005-08-19 | 2013-07-26 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
| WO2007047829A2 (en) | 2005-10-19 | 2007-04-26 | Laboratoires Serono S.A. | Novel heterodimeric proteins and uses thereof |
| GB0523954D0 (en) * | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
| AU2007257692B2 (en) * | 2006-06-12 | 2013-11-14 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
| KR20120117931A (ko) | 2010-02-12 | 2012-10-24 | 온코메드 파마슈티칼스, 인크. | 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013123061A1 (en) * | 2012-02-13 | 2013-08-22 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013142034A1 (en) | 2012-03-23 | 2013-09-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| EP2834270B1 (en) | 2012-04-05 | 2019-10-30 | AC Immune S.A. | Humanized tau antibody |
| US10358494B2 (en) * | 2013-05-03 | 2019-07-23 | Ohio State Innovation Foundation | CS1-specific chimeric antigen receptor engineered immune effector cells |
| EP3626748A1 (en) * | 2014-01-13 | 2020-03-25 | Stephen J. Forman | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
| EP3105317B1 (en) * | 2014-02-14 | 2018-09-19 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| JP2017518071A (ja) * | 2014-05-02 | 2017-07-06 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｃｓ１特異的多重鎖キメラ抗原受容体 |
| WO2016090369A1 (en) * | 2014-12-05 | 2016-06-09 | City Of Hope | Cs1 targeted chimeric antigen receptor-modified t cells |
| MX2019011225A (es) * | 2017-03-20 | 2020-01-21 | Células t modificadas por el receptor de antígeno quimérico dirigidas a cs1 para el tratamiento de la amiloidosis al. |
-
2015
- 2015-12-07 WO PCT/US2015/064303 patent/WO2016090369A1/en not_active Ceased
- 2015-12-07 MX MX2017007250A patent/MX384964B/es unknown
- 2015-12-07 BR BR112017011893-9A patent/BR112017011893A2/pt not_active Application Discontinuation
- 2015-12-07 US US15/533,153 patent/US10821161B2/en active Active
- 2015-12-07 CA CA2969704A patent/CA2969704C/en active Active
- 2015-12-07 CN CN202111214014.XA patent/CN114085856A/zh active Pending
- 2015-12-07 KR KR1020177018597A patent/KR102558502B1/ko active Active
- 2015-12-07 JP JP2017529682A patent/JP7098325B2/ja active Active
- 2015-12-07 CN CN201580075401.6A patent/CN107429253B/zh not_active Expired - Fee Related
- 2015-12-07 IL IL290459A patent/IL290459B2/en unknown
- 2015-12-07 EP EP15819937.2A patent/EP3227315B1/en not_active Not-in-force
- 2015-12-07 RU RU2017121826A patent/RU2727451C2/ru active
- 2015-12-07 AU AU2015357485A patent/AU2015357485B2/en not_active Ceased
- 2015-12-07 EP EP22208847.8A patent/EP4219530A1/en not_active Withdrawn
-
2017
- 2017-06-04 IL IL252645A patent/IL252645B/en active IP Right Grant
- 2017-06-05 MX MX2021008498A patent/MX2021008498A/es unknown
-
2020
- 2020-08-13 US US16/992,361 patent/US11730797B2/en active Active
-
2021
- 2021-01-11 AU AU2021200122A patent/AU2021200122B2/en not_active Ceased
- 2021-02-16 IL IL280917A patent/IL280917B/en unknown
-
2022
- 2022-01-07 JP JP2022001433A patent/JP7252379B2/ja active Active
-
2023
- 2023-07-10 US US18/349,678 patent/US12497440B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537627A5 (enExample) | ||
| Alnefaie et al. | Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions | |
| JP2019500894A5 (enExample) | ||
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| JP6968389B2 (ja) | Ｂｃｍａに結合するキメラ抗原受容体（ｃａｒ）及びその応用 | |
| JP2023139070A5 (enExample) | ||
| IL292650B2 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 | |
| JP2016538855A5 (enExample) | ||
| ES2800906T3 (es) | Métodos mejorados para producir terapias celulares adoptivas | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| JP2017500869A5 (enExample) | ||
| JP2018029594A5 (enExample) | ||
| JP2018532407A5 (enExample) | ||
| JP2019528769A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| BR112020007576A2 (pt) | composições e métodos para degradação de proteína seletiva | |
| JP2018518990A5 (enExample) | ||
| JP2018531014A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| JP2020513754A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| JP2017535292A5 (enExample) | ||
| FI3824905T3 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten |